Our ELISA assay offers an alternative approach to evaluating the p53 status of breast biopsy material, using cytosol extracts routinely prepared for steroid hormone receptor assays. This assay should also be of general application to other situations where the level of p53 protein needs to be determined.
Mutations of the tumour-suppressor gene p53 have been reported to be a frequent feature of carcinomas of the breast Nigro et al., 1989) , lung (Chiba et al., 1990; Iggo et al., 1990; Nigro et al., 1989; Takahashi et al., 1989) and colon Nigro et al., 1989; Rodrigues et al., 1990) and also of certain types of leukaemia (Ahuja et al., 1989) . These mutations are often missense mutations and accompany the loss of the wild-type allele on chromosome 17p, where the p53 gene is located.
Missense mutations in the p53 gene can result in the production of abnormal protein with novel oncogenic properties and a prolonged half-life (Lane & Benchimol, 1990; Levine et al., 1991) thereby leading to its accumulation in tumour cells Bartek et al., 1990; Nigro et al., 1989; Rodrigues et al., 1990; Takahashi et al., 1989) . Since the p53 protein does not usually accumulate in normal cells and is in effect undetectable by immunohistochemical and immunochemical techniques, the accumulation of p53 appears to be a potential novel marker for malignancy (Hall et al., 1991) and in certain tumour types is associated with poor prognosis (Cattoretti et al., 1988; Thor et al., 1992) .
A particular goal of breast cancer research has been the identification of tumour-associated markers which predict unfavourable prognosis and are independent of lymph node status and other prognostic factors (Callahan, 1992) . The accumulation of p53 protein has the potential to be one such marker in breast cancer (Thor et al., 1992 In this study we describe a two-site ELISA assay (Midgley et al., 1992; Vojtesek et al., 1992) (Bradford, 1976 (Hopwood et al., 1989) ) and embedded in paraffin wax. Three tLm sections were cut and stained with the anti-p53 polyclonal antibody CM1 (Midgley et al., 1992 ) using a peroxidase conjugated streptavidin biotin technique, as described by Midgley et al. (Midgley et al., 1992) . The use of phenol formalin fixations is particularly good for preserving the antigenicity of nuclear proteins, such as p53 (Midgley et al., 1992 & Lane, 1988) . The assay was standardised using pure soluble recombinant p53 isolated from bacteria (Midgley et al., 1992) . The protein) in the cytosol samples was calculated using the highest point from the linear range of the serial dilution series.
Results
The staining and ELISA results of 51 paired samples of tissue sections and cytosol extracts were compared (Table I) Figures 4a and b) . The results suggest that the assay is highly reproducible.
Discussion
There is increasing interest in the relationship between the presence of abnormal amounts of p53 protein in mammary carcinoma and the clinical outcome of the patients. Our own data (Barnes et al., 1993) and work by others (Thor et al., 1992) indicate that the presence of the protein is strongly associated with a short disease free interval and overall survival in node negative as well as node positive patients. %  IHC  ELISA  1  3  4  7  50  350  146  2  3  2  5  30  150  12   3  2  2  4  60  240  11  4  3  4  7  50  350  17  5  3  4  7  50  350  118  6  3  4  7  30  210  5  7  2  3  5  50  250  29  8  3  3  6  20  120  4  9  3  3  6  30  180  16  10  2  2  4  40  160  11  11  3  4  7  40  280  10  12  1  2  3  50  150  5  13  1  2  3  30  90  2  14  2  3  5  20  100  2  15  3  4  7  40  280  123  16  3  3  6  30  180  2 
1000
Cytosol extract protein (,ug ml-') Currently, there are numerous pilot studies on potential prognostic markers. An essential requirement for which is that the procedure for the assessment of a marker should be easy to perform and reproducible in a variety of laboratories. The development of the ELISA assay described in this paper fulfils this requirement and could facilitate definitive studies on the role of p53 in prognosis.
General molecular biology techniques involving the study of DNA using Southern blotting, polymerase chain reaction and direct DNA sequencing are not easily performed in clinical laboratories. An alternative method for detecting genetic abnormalities is the study of expression of the protein. While antibodies are available which can demonstrate the presence of p53 protein in routine archival blocks (Midgley et al., 1992; Vojtesek et al., 1992) these techniques are generally restricted to use in histopathology laboratories. Moreover, even when the same antibody is used there have been considerable differences in the interpretations of staining, in particular the degree of staining and the assessment of positivity (Cattoretti et al., 1988; Davidoff et al., 1992; Ostrowski et al., 1991; Thor et al., 1992) for comparable immunohistochemical studies. The ELISA assay we described here can be carried out on the cytosol extracts routinely prepared for the steroid hormone receptor assay. This means that the assay can be easily carried out in laboratories which already measure steroid hormone receptors. Whilst some structural forms of the p53 protein are heat-labile, the stringent collection procedures . .
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necessary for the receptor assay are also ideal for preserving the p53 protein for the ELISA assay. In this study we have shown that the ELISA assay is not quite as sensitive as the immunohistochemical technique, but this should not be a practical problem as our own preliminary data on prognosis (Barnes et al., 1993) has shown that it is the carcinomas in which more than 75% of the cells express the protein (Table  I category A and Table II ) which are associated with poor prognosis. This may have a simple genetic basis as it is these high levels of p53 that have generally shown a clear correlation with the expression of mutant p53 Davidoff et al., 1991a; Davidoff et al., 1991b) while low level expression of p53 may result from other processes such as DNA damage (Lu et al., 1992) . In in vitro systems high levels of mutant p53 are required for cellular transformation (Zambetti et al., 1992) . In the present study discrepancies between the two methods only occurred when fewer than 50% of the tumour cells expressed the protein.
It is inevitable that some discrepancy would be found between the results of the two assays since they were carried out on different pieces of tumour material. The immunohistochemical procedure was carried out on tumour tissue taken for diagnostic purposes. The ELISA assay was carried out on material selected for the receptor assay. In an attempt to ensure that the two pieces of tissue were similar, comparisons were made between the cellularity of tumour in the tissue selected for immunohistochemistry and that used in the ELISA assay. In all but one case the cellularity values were similar. The exception had a IHC score of 160 and a basal or zero ELISA value.
The ELISA assay of p53 in cytosols with these two new antibodies is much more sensitive than the previously available ELISA assays, which used monoclonal antibodies with lower affinity for the p53 protein or which specifically recognised a particular conformation of the p53 protein. Our monoclonal antibody DO-1 which we are using as a solid phase in the ELISA assay, is specific for a denaturationresistant epitope at the N-terminus (Vojtesek et al., 1992) and has a very high affinity for the p53 protein. While this paper has specifically examined the accumulation of p53 in breast biopsies, it is equally applicable to other tissues or cell lines and should be of widespread application for determining the levels of p53 protein. Since our assay uses commercially available antibodies (DO-1 is available from DAKO and Oncogene Sciences and CM1 is available from Nova Castra, Newcastle), and gives a simple quantitative result from normal cytosol preparations, it should be of wide application in determining if p53 levels can provide a basis for selecting patients that might benefit from different treatment protocols (Callahan, 1992; McGuire, 1991) .
